{"organizations": [], "uuid": "a4dcff8e2c17bf571dd869b08b7884276259b439", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/amgen-results/amgen-quarterly-profit-misses-2018-eps-outlook-ahead-of-street-view-idUSL2N1PJ2OD", "country": "US", "domain_rank": 408, "title": "Amgen quarterly profit misses, 2018 EPS outlook ahead of Street view", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-02T05:16:00.000+02:00", "replies_count": 0, "uuid": "a4dcff8e2c17bf571dd869b08b7884276259b439"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/amgen-results/amgen-quarterly-profit-misses-2018-eps-outlook-ahead-of-street-view-idUSL2N1PJ2OD", "ord_in_thread": 0, "title": "Amgen quarterly profit misses, 2018 EPS outlook ahead of Street view", "locations": [], "entities": {"persons": [{"name": "james dalgleish", "sentiment": "none"}, {"name": "bill berkrot", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amgen inc", "sentiment": "negative"}, {"name": "amgen", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Amgen Inc on Thursday reported fourth-quarter profit well below Wall Street estimates, as a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses hit results.\nBut the world’s biggest biotechnology company provided a 2018 earnings forecast range with a midpoint that easily exceeded analysts’ estimates and announced a new $10 billion share repurchase program and a lower effective tax rate due to U.S. tax reform.\nThe company posted a net loss of $4.26 billion, or $5.89 per share, as it took a $6.1 billion charge related to U.S. tax reform. That compared with a profit of $1.93 billion, or $2.59 per share, in the year-ago quarter.\nExcluding items, Amgen said it earned $2.89 per share. Analysts on average expected $3.03 per share, according to Thomson Reuters I/B/E/S. (Reporting by Bill Berkrot; Editing by James Dalgleish)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T05:16:00.000+02:00", "crawled": "2018-02-02T12:46:51.019+02:00", "highlightTitle": ""}